About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Combination Therapy Shows Good Results For Acute Myeloid Leukemia

by Julia Samuel on December 18, 2017 at 3:14 PM
Font : A-A+

Combination Therapy Shows Good Results For Acute Myeloid Leukemia

Venetoclax in combination with cobimetinib or idasanutlin for relapsed or refractory acute myeloid leukemia (AML) has a complete response in up to 50 percent patients.

The clinical trial followed patients who received therapy for a prior blood disease and who were not eligible for cytotoxic therapy.

Advertisement


Preliminary results from the ongoing dose-escalation study, demonstrate that the combination therapies can be safely administered with minimal side effects.

"This is the first clinical study evaluating new oral combinations with venetoclax in AML patients," said Konopleva. "This is significant as effective treatment options for patients with relapsed and/or refractory AML are limited."
Advertisement

Venetoclax, which inhibits the B-cell lymphoma protein (BCL-2) that makes cancer cells resistant to therapy, was previously FDA-approved for treatment of chronic lymphocytic leukemia (CLL).

Idasanutlin is an investigational drug targeting a protein called MDM2 which impacts the tumor suppressor gene p53, while cobimetinib targets a protein known as MEK within the cancer cell and is FDA-approved for treatment of advanced melanoma with BRAF mutation.

Andreeff and Konopleva also led the pre-clinical investigation resulting in the clinical trial. The pre-clinical research demonstrated unprecedented in vivo activity, as well as a new molecular mechanism explaining how the inhibitor drugs impact MDM2 which is tied to regulation of p53, and BCL2 - both linked to cell death.

Pre-clinical data also showed that venetoclax plus cobimetinib or idasanutlin may be synergistic. MEK and MDM2 inhibition have been shown to down-regulate a protein in the BCL-2 family, MCL-1, overcoming the major resistance mechanism to BCL-2 inhibition in AML.

"We demonstrated that p53 activation overcomes the resistance to BCL-2 inhibition by promoting MCl-1 degradation and overcoming cell death response by altering cellular response," said Andreeff.

"These findings laid the foundation for the development of the current combination clinical trial for AML, bringing together different investigations in my group that extended over 15 years."

Dose escalation is being used in the clinical trial to establish the maximum tolerated dose for each drug combination in the elderly patient with relapsed AML, an area of unmet need, according to Daver.

"The best response rates, up to 50 percent in relapsed AML, were seen for the combination of venetoclax and idasanutlin, in line with the preclinical data," he said. "However, these results will require confirmation in larger patient groups."

Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Advertisement
News Category
What's New on Medindia
Top 7 Benefits of Good Oral Hygiene
Healthy and Safer Thanksgiving 2021
Long-Term Glycemic Control - A Better Measure of COVID-19 Severity
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Leukemia Chronic Myeloid Leukemia Acute Myeloid Leukemia Acute Lymphoblastic Leukemia Reiki and Pranic Healing Multiple Myeloma Bone Marrow Transplantation Combination Therapy for High Blood Pressure Hairy Cell Leukemia 

Recommended Reading
Acute Lymphoblastic Leukemia
Acute lymphoblastic leukemia (ALL) is the cancer of white blood cells characterized by excess ......
Blood Cancer Treatment Outcome Depends on Genetic Make Up of Proteins
The genetic make-up can impact the activity of the immune system and the body's ability to fight ......
Combination Drug Therapy - A new strategy For Brain and Blood Cancers
Brain and Blood cancers can be treated by using drug combination as a new strategy, reveals study....
Tumor Suppressor Protein Promotes Deadly Form of Blood Cancer
The interaction between FLT3 mutations and RUNX1 activity in the induction of acute myeloid ......
Acute Myeloid Leukemia
Acute myeloid Leukemia, more popularly known by its abbreviated form AML, is a fast- evolving leukem...
Bone Marrow Transplantation
Preferred Term is Hematopoietic stem cell transplantation. In this stem cell from bone marrow are in...
Chronic Myeloid Leukemia
Chronic myeloid Leukemia is one of the most common types of blood cancer. It is characterized by ex...
Combination Therapy for High Blood Pressure
Anti-hypertensive agents are still the treatment drugs for hypertension but recent advances indicate...
Hairy Cell Leukemia
Hairy cell leukemia (HCL) is a type of leukemia where there are increased numbers of abnormal B-lymp...
Leukemia
Encyclopedia section of medindia gives general information about Leukemia...
Multiple Myeloma
Multiple Myeloma caught public attention when model turned actress Lisa Ray, who worked in Deepa Meh...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use